Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19726587 | 0.91 | — | — | |
| SCHEMBL18367682 | 0.80 | — | — | |
| SCHEMBL21419598 | 0.78 | ACHE (0.36) | ACHE | |
| SCHEMBL12391184 | 0.74 | ACHE (0.33) | ACHE | |
| SCHEMBL26772340 | 0.74 | — | — | |
| SCHEMBL21953543 | 0.73 | CYP19A1 (0.38) | — | |
| SCHEMBL2621618 | 0.73 | IDO1 (0.37) | — | |
| SCHEMBL24272193 | 0.71 | ACHE (0.39) | ACHE | |
| SCHEMBL22515608 | 0.71 | IDO1 (0.33) | — | |
| SCHEMBL19249773 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815818-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170008873-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008873-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | ACHE 3695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.